Drug Trial Radar · NCT02957682
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Last checked: Nov 20, 2026Latest source record: May 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,176
Actual
Start
Nov 2, 2016
Primary completion
Mar 5, 2020
Study completion Mar 5, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
Conditions
- Hypercholesterolemia
Interventions
Praluent (Alirocumab)Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96Time frame: Week 96
Locations
188 sites in 9 countries. Site status is shown where the registry gives one.
Regeneron Study Site
Auburn, Alabama
Regeneron Study Site
Birmingham, Alabama
Regeneron Study Site
Mobile, Alabama
Regeneron Study Site
Beverly Hills, California
Regeneron Study Site
Los Gatos, California
Regeneron Study Site
North Hollywood, California
Regeneron Study Site
Port Hueneme, California
Regeneron Study Site
Westminster, California
Regeneron Study Site 1
Aurora, Colorado
Regeneron Study Site 2
Aurora, Colorado
Regeneron Study Site
Colorado Springs, Colorado
Regeneron Study Site
Lake Worth, Florida
Regeneron Study Site
Lake Worth, Florida
Regeneron Study Site
Miami Springs, Florida
Regeneron Study Site
Covington, Georgia
Regeneron Study Site
Champaign, Illinois
Regeneron Study Site
Chicago, Illinois
Regeneron Study Site
Chicago, Illinois
Regeneron Study Site
Rock Island, Illinois
Regeneron Study Site
Evansville, Indiana
Regeneron Study Site
Indianapolis, Indiana
Regeneron Study Site
Ames, Iowa
Regeneron Study Site
Iowa City, Iowa
Regeneron Study Site
Waterloo, Iowa
Regeneron Study Site
Hutchinson, Kansas
Regeneron Study Site
Newton, Kansas
Regeneron Study Site
Overland Park, Kansas
Regeneron Study Site
Louisville, Kentucky
Regeneron Study Site
Bangor, Maine
Regeneron Study Site
Baltimore, Maryland
Regeneron Study Site
Oxon Hill, Maryland
Regeneron Study Site
Minneapolis, Minnesota
Regeneron Study Site
Olive Branch, Mississippi
Regeneron Study Site
Washington, Missouri
Regeneron Study Site
Buffalo, New York
Regeneron Study Site
New Hyde Park, New York
Regeneron Study Site
Cary, North Carolina
Regeneron Study Site
Charlotte, North Carolina
Regeneron Study Site
Charlotte, North Carolina
Regeneron Study Site
Greensboro, North Carolina
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.